Abcellera Biologics is trading 4.36% higher at $13.39 amid a broader biotech rally, with positive clinical-trial and regulatory news lifting sector sentiment; no clear company-specific announcement explains the gain.
- The company’s release page lists no announcement for October 27–28.
- Third-quarter results are scheduled for November 9.
- Major U.S. indexes were close to flat, making the sector trend more relevant than broad-market strength.